Patents by Inventor Robert Galemmo, JR.

Robert Galemmo, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20090270413
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing di-t-butyl phenyl piperazine derivatives of the general formula (1).
    Type: Application
    Filed: April 28, 2009
    Publication date: October 29, 2009
    Inventors: Robert Galemmo, JR., Gabriel Hum
  • CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20090270394
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted cyclylamine derivatives as shown in formulas (1).
    Type: Application
    Filed: April 28, 2009
    Publication date: October 29, 2009
    Inventors: Robert Galemmo, JR., Richard Holland, Gabriel Hum, Hossein Pajouhesh, Navjot Chahal, Mehran Seid-Bagherzadeh, Amy Girard
  • DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20090270338
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted N-cyclylalkyl-diphenylpropanamide derivatives as shown in formula (1).
    Type: Application
    Filed: April 28, 2009
    Publication date: October 29, 2009
    Inventors: Robert Galemmo, JR., Richard Holland, Gabriel Hum
  • Amino acid derivatives as calcium channel blockers
    Publication number: 20090012010
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both an amino acid functionality and multiple aromatic rings are disclosed of the general formula (1) where X is benzhydryl, or an aromatic or heteroaromatic ring.
    Type: Application
    Filed: May 14, 2008
    Publication date: January 8, 2009
    Applicant: Neuromed Phramaceuticals Ltd.
    Inventors: Robert Galemmo, JR., Richard Holland, Yanbing Ding, Lingyun Zhang, Gabriel Hum, Navjot Chahal, Joseph Duffy, Christian Stevenson, Andrew Ullman
  • N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
    Patent number: 7196110
    Abstract: The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell proliferative disorders.
    Type: Grant
    Filed: May 14, 2003
    Date of Patent: March 27, 2007
    Assignee: Janssen Phamaceutica N.V.
    Inventors: Chih Yung Ho, Bengt Anders Brunmark, Stuart Emanuel, Robert A. Galemmo, Jr., Dana L. Johnson, Donald W. Ludovici, Umar Maharoof, Jay M. Mei, Jan L. Sechler, Eric D. Strobel, Robert W. Tuman, Hwa Kwo Yen
  • Inhibitors of factor Xa with a neutral P1 specificity group
    Patent number: 6602895
    Abstract: The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: August 5, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert A. Galemmo, Jr., Celia Dominguez, John M. Fevig, Qi Han, Patrick Y. Lam, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan
  • Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors
    Patent number: 6548525
    Abstract: The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH2NH2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: April 15, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert A. Galemmo, Jr., Lori L. Bostrom, Donald J. P. Pinto, Karen A. Rossi
  • Inhibitors of factor Xa with a neutral P1 specificity group
    Patent number: 6403620
    Abstract: The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.
    Type: Grant
    Filed: September 10, 1999
    Date of Patent: June 11, 2002
    Inventors: Robert A. Galemmo, Jr., Celia Dominguez, John M. Fevig, Qi Han, Patrick Y. Lam, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan
  • Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
    Patent number: 6271237
    Abstract: The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH2NH2, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: August 7, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert A. Galemmo, Jr., Lori L. Bostrom, Donald J. P. Pinto, Karen A. Rossi
  • Inhibitors of factor Xa with a neutral P1 specificity group
    Patent number: 5998424
    Abstract: The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: December 7, 1999
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert A. Galemmo, Jr., Celia Dominguez, John M. Fevig, Qi Han, Patrick Y. Lam, Donald J. P. Pinto, James R. Pruitt, Mimi L. Quan
  • Substituted naphthylene compounds exhibiting selective leukotriene B.sub.4 antagonist activity
    Patent number: 5468898
    Abstract: This invention relates to bicyclic aryl compounds having selective LTB.sub.4 antagonist properties and comprising an amido substituent, a substituent group having a terminal carboxylic acid or derivative thereof and a lipophilic substituent, and to methods for the treatment of disorders which result from LTB.sub.4 activity and pharmaceutical compositions including such compounds.
    Type: Grant
    Filed: April 23, 1993
    Date of Patent: November 21, 1995
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chih Huang, Wan K. Chan, Charles A. Sutherland, Robert A. Galemmo, Jr.
  • Substituted monocyclic aryl compounds exhibiting selective leukotriene B.sub.4 antagonist activity
    Patent number: 5232948
    Abstract: Monocyclic aryl compounds having selective LTB.sub.4 antagonists properties and comprising an amido substituent, a substituent group having a terminal carboxylic acid or derivative thereof and a lipophilic substituent, therapeutic compositions and methods of treatment of disorders which result from LTB.sub.4 activity using the monocyclic aryl compounds are disclosed.
    Type: Grant
    Filed: September 10, 1990
    Date of Patent: August 3, 1993
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chih Huang, Wan K. Chan, Charles A. Sutherland, Robert A. Galemmo, Jr., Michael N. Chang
  • Disubstituted aryl compounds exhibiting selective leukotriene B4 antagonist activity
    Patent number: 5210208
    Abstract: Monocyclic and bicyclic aryl ring compounds having selective LTB.sub.4 properties and comprising two ring substituents, the first substituent comprising a lipophilic group and a terminal carboxylic acid or derivative group, and the second substituent comprising an amido group, therapeutic compositions and methods of treatment of disorders which result from LTB.sub.4 activity using the mono- and bicyclic aryl compounds are disclosed.
    Type: Grant
    Filed: September 24, 1990
    Date of Patent: May 11, 1993
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chih Huang, Wan K. Chan, Charles A. Sutherland, Robert A. Galemmo, Jr., Michael N. Chang
  • Quinoline derivatives as antagonists of leukotriene D4
    Patent number: 5166210
    Abstract: Quinolinyl styryl compounds and their use as pharmaceutical agents, particularly as lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties.
    Type: Grant
    Filed: July 2, 1991
    Date of Patent: November 24, 1992
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chi Huang, Robert A. Galemmo, Jr., Henry F. Campbell
  • Quinoline derivatives and their use as antagonists of leukotriene D.sub.4
    Patent number: 5059610
    Abstract: This invention relates to quinolinyl-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.
    Type: Grant
    Filed: April 20, 1990
    Date of Patent: October 22, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chi Huang, Robert A. Galemmo, Jr., Henry F. Campbell
  • Quinoline derivatives as antagonists of leukotriene D.sub.4
    Patent number: 5051427
    Abstract: This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.
    Type: Grant
    Filed: April 20, 1990
    Date of Patent: September 24, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chi Huang, Robert A. Galemmo, Jr., Henry F. Campbell
  • Quinoline derivatives as antagonists of leukotriene D4
    Patent number: 5028615
    Abstract: This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.
    Type: Grant
    Filed: April 20, 1990
    Date of Patent: July 2, 1991
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Fu-Chi Huang, Robert A. Galemmo, Jr., Henry F. Campbell
  • Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
    Patent number: 4977162
    Abstract: This invention relates to certain quinolinyl-chromone compounds and their use as valuable pharmaceutical agents, particularly as lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties.
    Type: Grant
    Filed: July 13, 1989
    Date of Patent: December 11, 1990
    Assignee: Rorer Pharmaceutical Corporation
    Inventors: Fu-Chih Huang, Henry F. Campbell, Keith S. Learn, Robert A. Galemmo, Jr.
  • Quinoline derivatives and use thereof as antagonists of leukotriene D.sub.4
    Patent number: 4920130
    Abstract: This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.
    Type: Grant
    Filed: November 3, 1987
    Date of Patent: April 24, 1990
    Assignee: Rorer Pharamceutical Corp.
    Inventors: Fu-chi Huang, Robert A. Galemmo, Jr., Henry F. Campbell
  • Quinoline derivatives and use thereof as antagonists of leukotriene D.sub.4
    Patent number: 4920131
    Abstract: This invention relates to quinolinyl compounds of the general formula: ##STR1## and the use of these compounds as pharmacological agents which are lipoxygenase inhibitors and/or leukotriene antagonists possessing anti-inflammatory and anti-allergic properties and their pharmaceutical compositions and processes for this preparation.
    Type: Grant
    Filed: June 21, 1988
    Date of Patent: April 24, 1990
    Assignee: Rorer Pharmaceutical Corp.
    Inventors: Fu-Chi Huang, Robert A. Galemmo, Jr., Henry F. Campbell